The reach of Lyme disease is expanding across the U.S., and cases may be under-reported. A recent CDC case report describes the experiences of two patients with fatal cases of Lyme carditis…
A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis
Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.
RheumPAC Announces New Donor Benefits in 2020
Donors at each giving level will receive recognition and special benefits at the ACR’s 2020 annual meeting.
15% E/M Services Reimbursement Hike a Win for Rheumatology
ACR advocacy leaders are celebrating a 15% planned increase in reimbursement for rheumatology evaluation and management services and are calling on members to thank Congress.
Changes & Additions to RISE Measures in 2020
Using RISE? Check out the updates for 2020, including five new measures available only through the RISE registry.
Increasing Opioid Dose May Not Help Chronic Pain
NEW YORK (Reuters Health)—In patients with chronic musculoskeletal pain, an increase in opioid dosage appears to be of no clear benefit, according to a two-year study. As Benjamin J. Morasco, PhD, tells Reuters Health by email, “When we followed patients with chronic pain, who were already prescribed long-term opioid therapy, we found patients as a…
Low-Dose Methotrexate Can Cause Adverse Effects
NEW YORK (Reuters Health)—Low-dose methotrexate can be associated with gastrointestinal, pulmonary, infectious, hematologic and other adverse effects, according to an analysis of the Cardiovascular Inflammation Reduction Trial (CIRT). “Methotrexate is not a benign drug, even at dosages used for rheumatic diseases,” Daniel H. Solomon, MD, MPH of Brigham and Women’s Hospital, Boston, tells Reuters Health…
Sodium-Glucose Cotransporter-2 Inhibitors May Decrease Gout Risk in Some Patients
Recent research assessed the risk of gout in patients with type 2 diabetes mellitus prescribed sodium-glucose cotransporter-2 (SGLT2) inhibitors compared with those prescribed a glucagon-like peptide-1 (GLP-1) agonist. The study found patients on the SGLT2 inhibitor had a lower rate of gout, suggesting SGLT2 inhibitors may actually reduce the risk of gout among this patient population…
Range of Insurance Issues Challenge Rheumatology
ACR representatives updated members on recent insurance issues…
A Public Health Approach to Arthritis: Experts Continue to Raise Awareness of Arthritis Burden
Public health agencies have been raising the profile of arthritis…
- « Previous Page
- 1
- …
- 96
- 97
- 98
- 99
- 100
- …
- 317
- Next Page »